WuXi PharmaTech has been awarded a certificate of Good Laboratory Practice (GLP) compliance for its toxicology facility in Suzhou, from the State Food and Drug Administration (SFDA), China's regulatory authority.

The certification covers single-dose and multiple-dose toxicology studies in both rodents and non-rodents, GeneTox studies, and toxicokinetic studies, and was issued following the SFDA’s review of WuXi’s management, personnel, test facilities, standard operating procedures, and study operations.

"This certificate from the SFDA is an important milestone in offering our clients toxicology studies that meet both domestic and international GLP quality standards for filing INDs both in China and other countries," said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech. "With this award, WuXi moves a step closer to achieving its goal of offering our pharmaceutical and biotech clients a comprehensive, fully integrated platform of pharmaceutical R&D services."